glp-1 obesity drug market forecast 2030 Obesity Drugs Market Research Report
Description
Both trials enrolled predominantly high-risk populations81% of LEADER and 83% of SUSTAIN-6 participants had established cardiovascular disease [3]
Cardio vs
ACG Clinical Guideline: Gastroparesis
Sandy Springs, GA - December 16, 2025 - Dr
A total of 225 participants were included in the modified intention-to-treat population and assigned to tirzepatide 10 mg ( n = 73), 15 mg ( n = 77), or placebo ( n = 75), alongside lifestyle modifications
